Tenaya Therapeutics, Inc.

NasdaqGS TNYA

Tenaya Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -86.16%

Tenaya Therapeutics, Inc. Return on Equity (ROE) is -86.16% for the Trailing 12 Months (TTM) ending September 30, 2024, a -36.30% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Tenaya Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -63.22%, a -29.83% change year over year.
Tenaya Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -48.69%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGS: TNYA

Tenaya Therapeutics, Inc.

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard
Employees	140
Sector	Healthcare
Industries Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends

Past 5 years